AstraZeneca : Feedback roadshow : une exécution qui surpasse les attentes
>Roadshow CFO & Head R&D Oncology : confiance retrouvée - Nous avons accompagné pour un roadshow parisien le CFO d’Astrazeneca Marc Dunoyer et le nouvel Head R&D Oncology Jose Baselga (Executive VP R&D Oncology) post publication des résultats FY 2018. Il en ressort que, suite à des doutes provenant des récents départs de managers (baisse du titre en janvier de 6000p à 5300p), la réorganisation rapide de la R&D et surtout la publication FY 2018 mi-février dernier, ont ...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.